Our US headquarters in Ridgefield, Connecticut, is home to one of Boehringer Ingelheim's leading research and development sites. More than 1,900 employees, working across disciplines, are based at the 330 acre site which runs completely on renewable, hydro-electric energy.
Consistently rated as a Global Top Employer and ranked number six in the 2023 Pharmaceutical Innovation Index, our mission is to discover and develop breakthrough therapies for patients. Through our innovation strategy, our dedicated scientists are doing just that. They're tackling some of the most difficult challenges in healthcare today and, together with our external research partners, are working to accelerate the next breakthroughs that will transform patients' lives now and for generations to come.
Dr. Carine Boustany
Senior Vice President
Site Head Discovery Research & Head of Global Immunology & Respiratory
At the Ridgefield Innovation Unit, and in partnership with our global team of scientists, we cultivate a culture that fosters creativity and puts the patient at the center of our work. Our scientific breakthroughs are testament to this mindset. We're always on the lookout for new team members who share our passion for science and who can bring that energy to work to discover and develop transformative therapies for patients.
Dr. Xiaorong He
Senior Vice President
Site Head Development US
Global Head of Development Science
Situated among the beautiful rolling hills of New England, it’s easy to forget that our campus is within easy driving distance of both New York City and Boston. Like the renown academic centers around us (several of which we partner with), Boehringer Ingelheim conducts cutting edge research and development activities with the potential to improve and extend the lives of patients around the world. As a privately held company, our resources and global reach allow us to follow the science not the stock market, investing in the needs of patients today, as well as those of future generations. Our talented scientists and leaders, together with our external partners, are continually creating value through innovation. If that sounds like a mission that motivates you, I encourage you to take your career to the next level at Boehringer Ingelheim!
Dr. Sudha Visvanathan
Vice President
Translational Medicine & Clinical Pharmacology (TMCP) Inflammation/TMCP US
The Translational Medicine team works in close collaboration with our Research colleagues to build the new therapeutic concepts into the right patient populations. This involves a variety of collaborations with key external experts to understand what is important in terms of the clinical characteristics of the patients and linking that to key biomarkers that are expressed in tissues and blood of patients. Our Clinical Pharmacology team work to characterize small/ large molecule drugs in healthy volunteers and patients in early and late phase trials. This is in partnership with our Pharmacometrics / Data Science team who is responsible for modelling the pharmacokinetics and pharmacodynamics of small / large molecule drugs. The culture of our team is very collaborative, scientific, & patient driven.